Healio: Pioglitazone benefits decrease after discontinuing therapy

March 22, 2016

The protective effect of pioglitazone on type 2 diabetes prevention observed in adults with impaired glucose tolerance diminishes in the months after discontinuing therapy, with participants randomly assigned the drug progressing to diabetes at a rate similar to those assigned placebo, according to an analysis of the ACT NOW study. Read the full story at […]

The Diabetes Times: Drug combination could prevent type 2 heart issues

February 15, 2016

The study, Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor, has been published in Diabetes, Obesity and Metabolism.  Researchers looked at the recently completed EMPA-REG study, which demonstrated that Empagliflozin significantly decreased major adverse cardiac events (MACE) in people with type 2 diabetes, deemed high risk. Read the full story at The Diabetes […]

Healio: Beta-cell function improved in men with Type 2 diabetes

January 18, 2016

Men with Type 2 diabetes who received acipimox as an add-on to 3 weeks of Farxiga therapy saw improved beta-cell function and beta-cell sensitivity to glucose beyond Farxiga alone; however, the addition of the lipolysis inhibitor did not cause further improvement in insulin sensitivity, according to research in The Journal of Clinical Endocrinology & Metabolism. […]

diabetes in men

MD Magazine: Source of GI dysfunction in Type 1 diabetes found

January 4, 2016

According to findings published in Cell Stem Cell, the cause of gastrointestinal symptoms in type 1 diabetes has been discovered. Researchers from the University of Texas Health Science Center at San Antonio compared intestinal tissues from diabetic patients and healthy individuals to determine the cause of chronic gastrointestinal symptoms such as gastroparesis, irritable bowel syndrome […]

Stomach pain

Research shows a cause of gastrointestinal symptoms in Type 1 diabetes

October 2, 2015

New research provides a molecular basis for why 80 percent of patients with longstanding Type 1 diabetes have chronic gastrointestinal symptoms including gastroparesis (delayed emptying of food), irritable bowel syndrome, abdominal distension and fecal incontinence, significantly reducing their quality of life.